Carol Mei, MD
Hematology & Oncology · Hollister, CANPI 1528041720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $369 and has fallen 78.0% since, to $81 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 48 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$179
- Amgen$147
- Novo Nordisk$146
- Boehringer Ingelheim$94
- Rigel Pharmaceuticals, Inc.$55
- Johnson & Johnson$55
- plus $450 from 17 others
What the payments were for
- Food & beverage$1,126100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 4 | $179 |
| Amgen | 2 | $147 |
| Novo Nordisk | 9 | $146 |
| Boehringer Ingelheim | 6 | $94 |
| Rigel Pharmaceuticals, Inc. | 3 | $55 |
| Johnson & Johnson | 3 | $55 |
| BD | 2 | $47 |
| Madrigal Pharmaceuticals | 1 | $38 |
| Dova Pharmaceuticals | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Merck | 1 | $29 |
| Medtronic(2 entities) | 2 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| AbbVie | 1 | $19 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,126 in reported general payments places this provider in the 35th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 24 | $288 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hollister
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.